Behavioral Innovation and Corporate Renewal
Strategic Management Review · 14.09.2021 · 2 (2) · 285-322
DOI: 10.1561/111.00000029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Strategic Management Review, online erschienen am 14.09.2021. Verfasst von Nathan R. Furr und 1 weiteren Autor:innen. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 131 Literaturangaben.
Abstract (Originalsprache)
Corporations often seek renewal through internal innovations that create new sources of revenue and help them enter new markets. But research and anecdote continue to show that corporations struggle to renew through innovation. We argue that the primary impediments to corporate renewal through innovation stem from the ways in which human–nature interacts with the inherently uncertain aspects of innovation. We suggest that the field needs to adopt a more integrated, behavioral innovation view to account for the behavioral forces shaping the innovation process. In this paper, we propose an alternate innovation process model that exposes key behavioral bottlenecks limiting innovation. We then review key extant findings and potential research opportunities related to the model. Finally, we highlight the importance of a research focus on remedies, as well as other future opportunities for the field. We hope this paper can serve as an inspiration for a new view of corporate renewal through innovation and for a behavioral innovation view more generally.
Zitieren
APA
Furr, N. R., & Eggers, J. P. (2021). Behavioral Innovation and Corporate Renewal. Strategic Management Review, 2(2), 285-322. https://doi.org/10.1561/111.00000029
Vancouver
Furr NR, Eggers JP. Behavioral Innovation and Corporate Renewal. Strategic Management Review. 2021;2(2):285-322. doi:10.1561/111.00000029
BibTeX
@article{Furr2021,
author = {Furr, Nathan R. and Eggers, J. P.},
title = {Behavioral Innovation and Corporate Renewal},
journal = {Strategic Management Review},
year = {2021},
volume = {2},
number = {2},
pages = {285--322},
doi = {10.1561/111.00000029}
}
EUVIMED